Teva Pharmaceutical Industries, a global leader in generic and innovative medicines, is issuing US$2.06bn (equivalent) of euro-denominated and US dollar-denominated sustainability-linked notes. Teva is rated Moody’s Ba2/Stable S&P BB-/Positive Fitch BB-/ Stable. Proceeds from the offering will partially fund a tender offer (along with cash on hand) as the company moves to manage and extend…